- Home
- VEL vs ACHV Comparison
VEL vs ACHV Comparison
Compare VEL & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | ACHV |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 765.5M | 618.0M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VEL | ACHV |
|---|---|---|
| Price | $17.18 | $6.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $22.00 | $14.67 |
| AVG Volume (30 Days) | 89.7K | ★ 2.7M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.98 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.01 | N/A |
| Revenue Next Year | $19.02 | N/A |
| P/E Ratio | $30.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.19 | $2.38 |
| 52 Week High | $21.40 | $7.11 |
Technical Indicators
Market Signals| Indicator | VEL | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 60.23 |
| Support Level | $16.97 | $4.09 |
| Resistance Level | $17.98 | $7.11 |
| Average True Range (ATR) | 0.53 | 0.44 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 4.97 | 53.70 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. Company operates in a large fragmented market with substantial demand for financing and limited supply of institutional financing alternative The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.